473 results on '"R. Gutzmer"'
Search Results
2. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation–positive melanoma
3. Key Clinical Adverse Events in Patients with Advanced Basal Cell Carcinoma Treated with Sonidegib or Vismodegib: A Post Hoc Analysis
4. 813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study
5. Kutanes Plattenepithelkarzinom
6. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis
7. Aggressive gamma/delta T-cell lymphoma: successful therapy with encapsulated doxorubicin
8. Histamine Increases Th2 Cytokine-Induced CCL18 Expression in Human M2 Macrophages
9. Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAF
10. 828P Effectiveness and safety of dabrafenib and trametinib in patients with BRAFV600 mutated metastatic melanoma in the real-world setting: Final results of the non-interventional COMBI-r study
11. 786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma
12. The effect of mogamulizumab on the malignant T cell population: a monocentric retrospective analysis
13. 787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
14. Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
15. Response to letter entitled: ‘Re: Hematological immune related adverse events after treatment with immune checkpoint inhibitors’
16. Expression of histamine receptors H2R and H4R are predominantly regulated via the IL-4/IL-13 receptor type II on human M2 macrophages
17. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
18. 149P KEYNOTE-629: Efficacy of pembrolizumab (Pembro) per immune-related RECIST (irRECIST) in locally advanced (LA) and recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC)
19. 1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
20. IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy
21. Corrigendum to ‘IgE blockade in the management of eosinophil-associated recalcitrant pruritus due to medical tumor therapy’
22. Aktueller Stand bei nichtmelanozytären Hauttumoren
23. 1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
24. 1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS
25. Sequence-dependent cross-resistance of combined radiotherapy plus BRAF
26. PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma
27. 1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study
28. Rolle von Histamin und seiner spezifischen Rezeptoren, insbesondere des Histamin- H4-Rezeptors, bei chronisch-entzündlichen Hautkrankheiten
29. [Cutaneous squamous cell carcinoma]
30. Contents Vol. 227, 2013
31. [Systemic treatment of inoperable metastasized malignant melanoma]
32. Life expectancy in primary myelodysplastic syndromes: A prognostic score based upon histopathology from bone marrow biopsies of 569 patients
33. Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis
34. Prognostic significance of histopathological parameters in sentinel nodes of melanoma patients
35. Colorectal Cancer Vaccines: Antiidiotypic Antibody, Recombinant Protein, and Viral Vector
36. Seltener Tumor der Nasenhöhle versteckt in einer ausgeprägten Polyposis nasi
37. 15. Mainzer Allergie-Workshop 2003
38. [Cutaneous squamous cell carcinoma: a review with consideration of special patient groups]
39. [Cutaneous side effects of anti-tumor therapy with BRAF and MEK inhibitors]
40. Dermatoonkologie
41. 3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria
42. 3323 The GERMELATOX DeCOG-trial: The attitude of German melanoma patients towards toxicity during adjuvant interferon treatment - Differences between the patient's and the physician's perspective
43. 3338 Initial safety results from a multinational, prospective, observational study in advanced melanoma (MEL) (IMAGE)
44. [Rare tumor of the nasal cavity hidden in a nasal polyposis]
45. [Squamous cell carcinoma developing in oral lichen planus]
46. Comparison of scoring systems in primary myelodysplastic syndromes
47. Malignes Melanom
48. [Remission of an iatrogenic Kaposi sarcoma in a patient with myasthenia gravis after switching immunosuppressive therapy to the mTOR inhibitor everolimus]
49. Enhanced postoperative lymphatic staging of malignant melanoma by endoscopically assisted iliacoinguinal dissection
50. [Cutaneous side effects of medical tumor therapy]
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.